SAN DIEGO– January [24]2023 — Vividion Therapeutics, Inc., (Vividion) a biopharmaceutical business making use of unique discovery innovations to open high worth, generally undruggable targets with accuracy rehabs for ravaging cancers and immune conditions, and an entirely owned and individually ran subsidiary of Bayer AG, today revealed that present President and Head of Research and Development Aleksandra Rizo, M.D., Ph.D., will presume the function of President and Chief Executive Officer of Vividion and will sign up with the Board of Directors. Jeffrey Hatfield, present Chief Executive Officer, will shift to the position of Chairman of the Board of Directors at Vividion. Vividion will continue its objective to unlock high worth, generally undruggable target biology with accuracy rehabs for cancers and immune conditions.
Under Jeffrey Hatfield’s management given that 2020, Vividion has actually grown from a little, research study start-up to a mid-sized effective biotech business with almost 200 workers. The business is currently advancing several unique biology, first-in-class programs towards the center and has more than a lots comparable pipeline chances emerging in early discovery. In his brand-new function, Jeffrey Hatfield will continue to take an active function in the development and maturation of Vividion towards a clinical-stage business, supplying assistance and assistance on both business and R&D method.
“It is an exceptionally amazing time at Vividion, as we are beginning to advance numerous programs from our chemoproteomics platform in the center and our research study pipeline and tactical collaborations continue to speed up, stated Jeffrey Hatfield. “I’m deeply grateful for the chance over the previous 2 years to lead this first-rate group at Vividion, and to partner with Bayer to recognize our complete capacity. In my brand-new function as Board Chair, I anticipate continuing to deal with the Board and Aleksandra to bring our accuracy rehabs to the clients who frantically require them.”
“Jeff has